



Detroit R&D, Inc.
Metro Center for High Technology Bldg.
2727 Second Ave. Suite 4113
Detroit, MI 48201
Phone: (313) 961-1606; Fax: (313)963-7130
Email: info@DetroitRandD.com
Web: www.DetroitRandD.com

Reference for 14,15-EET/DHET ELISA Kits

Catalog Number: **DH2/DH12/DH22**

References:

1. Kim et al. Three US Patents: 14,15 and 11,12-DHET dependent hypertension 6,440,682, 6,534,282 and 7,695,927 issued on 8/27/2002, 3/18/2003 & 4/13/2010 respectively. (<http://patft.uspto.gov/netahtml/srchnum.htm>)
2. Spiecker et al. Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. *Circulation*. 110, 2132-2136, 2004.
3. Garson, Kim et al. Computational characterization of a series of eicosanoids. *Lett. Drug Design & Discovery*. 2, 322-325, 2005.
4. Wang et al. Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors. *Cancer Res*. 65, 4707-4715, 2005.
5. Alkayed et al. Polymorphisms in the human soluble epoxide hydrolase gene EPHX2 linked to neuronal survival after ischemic injury. *J. Neurosci*. 27, 464-4649, 2007.
6. Wang et al. Cytochrome P-450 epoxygenase promotes human cancer metastasis. *Cancer Res*. 67, 6665-6667, 2007.
7. Zeldin et al. Cytochrome P-450 epoxygenases protect endothelial cells from apoptosis induced by tumor necrosis factor- α via MAPK and PI3K/Akt signaling pathways. *Am. J. Physiol. Heart Circ. Physiol*. 293, H142-H151, 2007.
8. Chen et al. Synergistic effect of cytochrome P450 epoxygenase CYP2J2*7 polymorphism with smoking on the onset of premature myocardial infarction. *Atherosclerosis*, 195, 199-206, 2007.
9. Alkayed et al. Soluble epoxide hydrolase gene deletion is protective against experimental cerebral ischemia. *Stroke*. 39, 2073-2078, 2008.
10. Wang et al. Selective inhibitors of CYP2J2 related to terfenadine exhibit activity strongly against human cancers *in vitro* and *in vivo*. *J. Pharmacol. Exp. Ther*. 329, 908-918, 2009.
11. Alkayed et al. Role of soluble epoxide hydrolase in the sex-specific vascular response to cerebral ischemia. *J. of Cerebral Blood Flow & Metabolism*. 29, 1475-1481, 2009.
12. Eldrup et al. Structure based optimization of arylamides as inhibitors of soluble epoxide hydrolase. *J. Med. Chem*. 52, 5880-5889, 2009.
13. Wang et al. Gene delivery of a cytochrome P-450 epoxygenase ameliorates. *Am. J. Respir. Cell Mol. Biol*. 10, 1-36, 2010.
14. Ding et al. Novel SHE inhibitors and their use. US Patent application Pub. No: 0069391, 2010.